Producer
Lifecore Biomedical LLC
US pharmaceutical-grade sodium hyaluronate manufacturer and CDMO; only US-based producer of injectable-grade HA via microbial fermentation; >20 commercially approved HA products including ophthalmic OVDs; producing since 1994.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Lifecore Biomedical LLC supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Lifecore Biomedical LLC makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Pharmaceutical-Grade Sodium Hyaluronate (HA)
55%CDMO Services (Sterile Fill-Finish)
45%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2024
Aurolab (Aravind Eye Care System, Madurai, India) manufactures IOLs, surgical sutures, blades, and ophthalmic pharmaceuticals for 130+ countries. Its PMMA IOL brought cost from $100+ to $3, and it has produced >20 million IOLs. Aurolab expanded its eye drops manufacturing with a Rs.100 crore ($12M) investment in 2025. A hospital's internal workshop became a globally significant ophthalmic supply chain node — a classic origin story of mission-driven manufacturing outscaling commercial players.
Aravind Eye Care System ↗Concentration2023
Lifecore Biomedical (Chaska, Minnesota; formerly Lifecore Biomedical, now part of Landec Corporation/LNDC) is the only US manufacturer of pharmaceutical-injectable-grade sodium hyaluronate — the material used in ophthalmic viscosurgical devices (OVDs) for cataract surgery and in dry-eye therapeutic drops. The US performs approximately 4 million cataract surgeries annually; virtually every one requires OVD injection to protect the corneal endothelium during the procedure. If Lifecore's Chaska MN facility were disrupted — from a tornado (Minnesota is in the US tornado corridor), a flooding event from the Minnesota River, or regulatory suspension — the US would have essentially no domestic pharmaceutical HA production, relying entirely on Japanese imports (Kewpie, Shiseido, Seikagaku) for cataract surgery materials. A single small-city Minnesota pharmaceutical fermentation plant is the sole US source for an ingredient required in every US cataract surgery. Cataract surgery is the most commonly performed surgery in the US (and world) — its supply chain has a single US production node in a mid-sized Minnesota suburb.
Lifecore Biomedical ↗Did you know2023
Sodium hyaluronate (HA) from Lifecore's Chaska fermentation plant serves three completely separate medical and aesthetic markets from the same biomaterial: (1) Cataract eye surgery — ophthalmic viscoelastic devices (OVD) containing HA are injected into the anterior chamber during cataract lens replacement surgery; OVD protects the corneal endothelium from mechanical damage; approximately 4 million US cataract procedures/year use HA-based OVD; (2) Cosmetic dermal fillers — the Juvederm and Restylane products that add facial volume and reduce wrinkles in aesthetic medicine clinics are crosslinked HA gels manufactured from pharmaceutical-grade HA; (3) Arthritis viscosupplementation — HA is injected into knee joints to supplement natural joint fluid and relieve osteoarthritis pain; Euflexxa and other viscosupplementation products serve millions of US knee pain patients. The same biological molecule (a glycosaminoglycan found naturally in human joint fluid and vitreous humor) serves an 85-year-old cataract surgery patient losing vision, a 45-year-old seeking facial rejuvenation, and a 60-year-old with osteoarthritis knee pain — medically, aesthetically, and orthopedically simultaneously.
Lifecore Biomedical LLC ↗